Induced pluripotent stem cells (iPSCs) have the potential to transform drug discovery and healthcare in the 21(st) century. However, successful commercialization will require standardized manufacturing platforms. Here we highlight the need to define standardized practices for iPSC generation and processing and discuss current challenges to the robust manufacture of iPSC products.
|Number of pages||5|
|Journal||Cell stem cell|
|Publication status||Published - 8 Jan 2015|
Bibliographical noteCopyright © 2015 Elsevier Inc. All rights reserved.
- Cell Culture Techniques/methods
- Cellular Reprogramming
- Induced Pluripotent Stem Cells/cytology
- Reproducibility of Results
- Stem Cell Transplantation